Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
We describe a novel classification system for local recurrence after surgery for renal cell carcinoma, and assess its prognostic implications using prospective randomized controlled data. The ASSURE (ECOG-ACRIN E2805) trial data were queried for patients with fully resected intermediate-high risk non-metastatic renal cell carcinoma with local recurrence using the following definitions: Type I: single recurrence in remnant kidney or ipsilateral renal fossa; Type II: single recurrence in ipsilateral vasculature, ipsilateral adrenal gland, or lymph node; Type III: single recurrence in other intra-abdominal soft tissues or organs; and Type IV: any combination of Types I-III, or multiple recurrences within a single Type. Multivariable logistic regression and log-rank test were used to identify clinicopathologic predictors and compare survival, respectively. Of 300/1,943 (15.4%) patients with local recurrence, 66/300 (22.0%) had Type I, 97/300 (32.3%) had Type II, 87/300 (29.0%) had Type III, and 50/300 (16.7%) had Type IV. Surgical modality (minimally-invasive versus open) and type of surgery (partial versus radical) did not predict any local recurrence. Five-year cancer-specific (p<0.001) and overall (p<0.001) survival were worse for patients with Type IV recurrence. There was no difference in survival among patients with Types I-III recurrences. In patients with intermediate-high risk non-metastatic renal cell carcinoma, local recurrence appears to be a function of biology more than surgical modality or type of surgery. The prognosis for solitary intra-abdominal local recurrences appear similar regardless of location (Types I-III). Local recurrences involving multiple sites and/or subdivisions is associated with worse survival (Type IV).